• 1
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 11914.
  • 2
    Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001; 285: 19969.
  • 3
    Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002; 287: 28014.
  • 4
    Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002; 287: 28134.
  • 5
    Bhandari M, Guyatt GH, Lochner H, Sprague S, Tornetta P 3rd. Application of the Consolidated Standards of Reporting Trials (CONSORT) in the Fracture Care Literature. J Bone Joint Surg Am 2002; 84-A: 4859.
  • 6
    Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials 2002; 23: 3808.
  • 7
    Clarke M, Alderson P, Chalmers I. Discussion sections in reports of controlled trials published in general medical journals. JAMA 2002; 287: 2799801.
  • 8
    Clarke M, Chalmers I. Discussion sections in reports of controlled trials published in general medical journals: islands in search of continents? JAMA 1998; 280: 2802.
  • 9
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 40812.
  • 10
    Schulz KF. Subverting randomization in controlled trials. JAMA 1995; 274: 14568.
  • 11
    Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol 2002; 55: 78790.
  • 12
    Schindel L. The placebo dilemma. Eur J Clin Pharmacol 1978; 13: 2315.
  • 13
    Yank V, Rennie D. Reporting of informed consent and ethics committee approval in clinical trials. JAMA 2002; 287: 28358.
  • 14
    Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ 2001; 165: 133941.
  • 15
    Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 43743.
  • 16
    Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials—a systematic survey. BMC Clin Pharmacol 2001; 1: 3.
  • 17
    Lexchin J, Bero L, Djulbegovic B. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J 2003; 326: 116770.
  • 18
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 15974.
  • 19
    Soares HP, Daniels S, Kumar A et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. Br Med J 2004; 328: 224.
  • 20
    Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003; 138: W112.